Serotonin (5-HT) is an important neurotransmitter mediator in the peripheral and central nervous system. Serotonin 5-HT_1A receptors have been intensively studied because of their implication in several physiological processes and psychiatric disorders such as anxiety and depression. 5-HT_1A receptor ligands with serotonin transporter inhibition effect are regarded as potential therapeutics for anxiety, depression. Moreover the chemical structure of synthesized ligands may be responsible for pre- and post-synapsis agonism or antagonism effect on 5-HT_1A receptors.

Although the main investigated structures were buspirone and tandospirone, many modifications have been made in the pharmacophoric and non-pharmacophoric part of potential 5-HT_1A receptors ligands.

All novel 4-aryl-2H-pyrido[1,2-c]pyrimidine derivatives containing quinoline substituents were confirmed by¹H and ¹³C NMR spectra and elementar analysis. Target compounds were assesed for in vitro affinity for serotoninergic 5-HT_1A and 5-HT_2A receptors and 5-HT-T.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/14693 must be provided.

1. Serotonin transporter inhibitors inducing hypothermia at mice
2. Rational design and synthesis of new 5-HT₆R ligands with the use of bioisosteric strategies. Crystal structures, biological evaluation and molecular modeling studies.
3. Ligand-directed receptor trafficking
4. Synthesis, anticonvulsant activity and 5-HT_1A/5-HT₇ receptors affinity of new 1-[(4-substituted-  piperazin-1-yl)-alkyl]- 3-methyl- 3-(2-methylpropyl)-pyrrolidine- 2,5-diones
5. The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of arylxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists
6. Homology modeling of G-protein coupled receptors
7. Identification of Novel 5-HT₇R Ligands via Multistep Virtual Screening of Commercially Available Compounds Databases
8. Examination of 5-HT₆ receptor affinity in the group of arylsulfonamide derivatives
9. Interaction fingerprints patterns. Binding mode analysis of mGlu2 receptor model based on docking studies
10. Quinolinesulfonamides as potential 5-HT₇ and 5-HT_1A receptor ligands
11. Alkyl-nitroquipazine derivatives as serotonin transporter and 5-HT_1A receptor ligands
12. CHO cell line with stable expression of the HTRA1 gene as a tool for studying functional activity of 5-HT_1A receptor ligands
13. A novel synthesis of 19-nor analogs of vitamin D
14. Synthesis of long-chain arylpiperazine theophylline derivatives as potential 5-HT₇ and 5-HT₆ receptors ligands
15. The determination of chromatografic purity of Pramipexole Dihydrohloride Monohydrate
16. The cytotoxic activity of glycosides of indolo[2,3-b]quinoline derivatives.
17. Searching for lead molecules as potential new CNS agents in the serotonin 5-HT₆ screening assay
18. Mannich bases, 5-arylimidazolidine-2,4-dione derivatives with arylpiperazine moiety, as 5-HT_1A receptor ligands with serotonin transporter affinity
19. Crystal structure of β-adrenergic receptor as a new template in homology modeling of GPCR. Application to serotonin 5-HT_1A and 5-HT₇ receptors
20. Solid-phase synthesis and preliminary biological investigation of arylpiperazine library as 5-HT_1A and 5-HT_2A receptor ligands
21. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT_1A activity. Part 1.
22. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT_1A activity. Part 2.
23. 2-(1-Arylsulfonylpiperidin-2-yl)ethyl derivatives as 5-HT₇ receptor ligands: synthesis and their affinity for 5-HT_1A/5-HT_2A/5-HT₇/D₂ receptors
24. SAR studies of novel 5-HT₇R ligands with different spacers between aryl and amine moieties
25. New serotonin receptors ligands in the group of 8-acylamide derivatives of 1,3-dimethyl-7-[(4-phenyl- piperazin-1-yl)-alkyl]-1H-purine-2,6-(3H,7H)-dione
26. Synthesis and serotonin receptors activity of new purine-2,6-dione derivatives with arylpiperazinylalkoxy moieties
27. Molecular modeling explains differences in binding affinity of new potent and selective 5-HT_1A ligands: arylpiperazinylalkylthiobenzoxazole derivatives
28. The ligand binding to the serotonin transporter
29. HPLC AS A METHOD FOR ANALYTICAL CONTROL OF SYNTHESIS AND DETERMINATION OF PRAMIPEXOLE
30. NEW DUAL 5-HT₇/5-HT_1A LIGANDS WITH ANTIDEPRESSANT AND ANXIOLYTIC-LIKE ACTIVITY
31. MONO SUBSTITUTED 5H-INDOLO[2,3-B]- QUINOLINE DERIVATIVES AND THEIR ABILITY TO OVERCOME THE BARRIER OF DRUG RESISTANCE.
32. SYNTHESIS OF NEW 4,5-DIHYDRO- 3aH-IMIDAZO[1,5-a]QUINOLINE DERIVATIVES AS 5-HT_1A SEROTONIN RECEPTOR LIGANDS.
33. NEW PERHYDRO-PYRROLO[1,2-a]PYRAZINE DERIVATIVES WITH AN ARYLPIPERAZINE MOIETY AS LIGANDS FOR 5-HT_1A RECEPTOR.
34. THE BIOLOGICAL TARGET DERIVED PHARMACOPHORIC MODEL FOR 5-HT₇ SEROTONIN RECEPTOR ANTAGONISM
35. NOVEL 4-ARYL-2H-PYRIDO[1,2-c]PYRIMI- DINES WITH 5-HT-TRANSPORTER AND 5-HT_1A AFFINITY
36. SYNTHESIS OF 8-FURFURYLTROPANE BENZAMIDE DERIVATIVES WITH POTENTIAL ANTIPSYCHOTIC ACTIVITY
37. 8-ALKOXY-PURINE-2,6-DIONES WITH 7-PHENYLPIPERAZINYLALKYL AND 7-TETRAHYDRO-ISOQUINOLINYLALKYL MOIETIES AS 5-HT_1A, 5-HT_2A, 5-HT₇ RECEPTOR LIGANDS
38. DESIGN AND SYNTHESIS OF NEW 7-PHENYLPIPERAZINYLALKYL AND 7-TETRAHYDROISOQUINOLINYLALKYL DERIVATIVES OF PURINE-2,6,8-TRIONE AS POTENTIAL SEROTONIN RECEPTOR AGENTS
39. A NEW, EFFICIENT AND ECONOMIC METHOD FOR PREPARATION OF PRAMIPEXOLE.
40. ¹H AND ¹³C NMR DATA FOR INDOLO[2,3-b]QUINOLINES - AMINOGLYCOSIDE HYBRIDS, A NOVEL POTENT ANTICANCER DRUG FAMILY .